Ftse Mib
34.761,97
0,00%
DAX
18.774,71
0,43%
S&P 500
5.304,72
0,70%
NASDAQ
16.920,79
1,10%
Bitcoin
67.993,69
-2,02%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Regno Unito LSE Sandoz Group Ag (0SAN) Sandoz Group Ag (0SAN) Notizie

0SAN

Sandoz (0SAN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:LSE:0SAN
DataOraFonteTitoloSimboloCompagnia
22/05/202407:00UK RegulatorySandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in EuropeLSE:0SANSandoz Group Ag
07/05/202407:00UK RegulatorySandoz reports first quarter 2024 salesLSE:0SANSandoz Group Ag
30/04/202412:25UK RegulatoryShareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AGLSE:0SANSandoz Group Ag
30/04/202407:00UK RegulatorySandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilarsLSE:0SANSandoz Group Ag
22/04/202407:00UK RegulatorySandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offeringLSE:0SANSandoz Group Ag
21/03/202414:00UK RegulatorySandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicinesLSE:0SANSandoz Group Ag
13/03/202407:00UK RegulatorySandoz reports fourth quarter 2023 sales and full-year 2023 resultsLSE:0SANSandoz Group Ag
05/03/202419:24UK RegulatorySandoz receives FDA approval for first and only denosumab biosimilarsLSE:0SANSandoz Group Ag
05/03/202407:00UK RegulatorySandoz announces nominations to the Board of Directors and leadership changeLSE:0SANSandoz Group Ag
04/03/202407:00UK RegulatorySandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US marketLSE:0SANSandoz Group Ag
29/02/202407:00UK RegulatorySandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffsLSE:0SANSandoz Group Ag
01/02/202407:15UK RegulatorySandoz announces changes in the Board of DirectorsLSE:0SANSandoz Group Ag
31/01/202407:00UK RegulatorySandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in GermanyLSE:0SANSandoz Group Ag
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:LSE:0SAN

La tua Cronologia

BIT
11COV
Covestro
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network